Cargando…
A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain
We performed a systematic review and meta-analysis of randomised controlled trials (RCTs) conducted from January 2005 to June 2021 to update the evidence of Botulinum toxin A (BoNT-A) in neuropathic pain (NP) in addition to quality of life (QOL), mental health, and sleep outcomes. We conducted a Coc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780616/ https://www.ncbi.nlm.nih.gov/pubmed/35051013 http://dx.doi.org/10.3390/toxins14010036 |
_version_ | 1784637887739854848 |
---|---|
author | Datta Gupta, Anupam Edwards, Suzanne Smith, Jessica Snow, John Visvanathan, Renuka Tucker, Graeme Wilson, David |
author_facet | Datta Gupta, Anupam Edwards, Suzanne Smith, Jessica Snow, John Visvanathan, Renuka Tucker, Graeme Wilson, David |
author_sort | Datta Gupta, Anupam |
collection | PubMed |
description | We performed a systematic review and meta-analysis of randomised controlled trials (RCTs) conducted from January 2005 to June 2021 to update the evidence of Botulinum toxin A (BoNT-A) in neuropathic pain (NP) in addition to quality of life (QOL), mental health, and sleep outcomes. We conducted a Cochrane Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria analysis of RCTs from the following data sources: EMBASE, CINAHL, WHO International Clinical Trial Registry Platform, ClinicalTrials.gov, Cochrane database, Cochrane Clinical Trial Register, Australia New Zealand Clinical Trials Registry, and EU Clinical Trials Register. Meta-analysis of 17 studies showed a mean final VAS reduction in pain in the intervention group of 2.59 units (95% confidence interval: 1.79, 3.38) greater than the mean for the placebo group. The overall mean difference for sleep, Hospital Anxiety and Depression Scale (HADS) anxiety, HADS depression, and QOL mental and physical sub-scales were, respectively, 1.10 (95% CI: −1.71, 3.90), 1.41 (95% CI: −0.61, 3.43), −0.16 (95% CI: −1.95, 1.63), 0.85 (95% CI: −1.85, 3.56), and −0.71 (95% CI: −3.39, 1.97), indicating no significance. BoNT-A is effective for NP; however, small-scale RCTs to date have been limited in evidence. The reasons for this are discussed, and methods for future RCTs are developed to establish BoNT-A as the first-line agent. |
format | Online Article Text |
id | pubmed-8780616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87806162022-01-22 A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain Datta Gupta, Anupam Edwards, Suzanne Smith, Jessica Snow, John Visvanathan, Renuka Tucker, Graeme Wilson, David Toxins (Basel) Review We performed a systematic review and meta-analysis of randomised controlled trials (RCTs) conducted from January 2005 to June 2021 to update the evidence of Botulinum toxin A (BoNT-A) in neuropathic pain (NP) in addition to quality of life (QOL), mental health, and sleep outcomes. We conducted a Cochrane Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria analysis of RCTs from the following data sources: EMBASE, CINAHL, WHO International Clinical Trial Registry Platform, ClinicalTrials.gov, Cochrane database, Cochrane Clinical Trial Register, Australia New Zealand Clinical Trials Registry, and EU Clinical Trials Register. Meta-analysis of 17 studies showed a mean final VAS reduction in pain in the intervention group of 2.59 units (95% confidence interval: 1.79, 3.38) greater than the mean for the placebo group. The overall mean difference for sleep, Hospital Anxiety and Depression Scale (HADS) anxiety, HADS depression, and QOL mental and physical sub-scales were, respectively, 1.10 (95% CI: −1.71, 3.90), 1.41 (95% CI: −0.61, 3.43), −0.16 (95% CI: −1.95, 1.63), 0.85 (95% CI: −1.85, 3.56), and −0.71 (95% CI: −3.39, 1.97), indicating no significance. BoNT-A is effective for NP; however, small-scale RCTs to date have been limited in evidence. The reasons for this are discussed, and methods for future RCTs are developed to establish BoNT-A as the first-line agent. MDPI 2022-01-03 /pmc/articles/PMC8780616/ /pubmed/35051013 http://dx.doi.org/10.3390/toxins14010036 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Datta Gupta, Anupam Edwards, Suzanne Smith, Jessica Snow, John Visvanathan, Renuka Tucker, Graeme Wilson, David A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title | A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title_full | A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title_fullStr | A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title_full_unstemmed | A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title_short | A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain |
title_sort | systematic review and meta-analysis of efficacy of botulinum toxin a for neuropathic pain |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780616/ https://www.ncbi.nlm.nih.gov/pubmed/35051013 http://dx.doi.org/10.3390/toxins14010036 |
work_keys_str_mv | AT dattaguptaanupam asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT edwardssuzanne asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT smithjessica asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT snowjohn asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT visvanathanrenuka asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT tuckergraeme asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT wilsondavid asystematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT dattaguptaanupam systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT edwardssuzanne systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT smithjessica systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT snowjohn systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT visvanathanrenuka systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT tuckergraeme systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain AT wilsondavid systematicreviewandmetaanalysisofefficacyofbotulinumtoxinaforneuropathicpain |